The role of CRISPR in controlling TNBC using theBRCA۱ and BRCA۲ genes

Genome-wide association studies (GWASs) risk of breast cancer withgermline pathogenic modifications in cancer alternative genes are criticallyrequired for risk evaluation and control in women with acquired pathogenicmodifications. Breast cancer (BC) is the most prevalent type of cancer inwomen mutations of BRCA۱ and BRCA۲ occur in patients with a familyhistory which is one of the predisposing genes to breast cancer development.triple-negative breast cancer (TNBC) are negative for the PR, ER, and HER-۲ hormone receptors, and are therefore called triple-negative which areregularly observed inside and on the surface of normal breast cells. Inspecial, these hormones are involved in promoting tumorigenesis. most ofthe treatments are ineffective such as inhibitors medications, hormonetherapy, chemotherapy, and radiation therapy of TNBC, and progressive thanother types of BC tumors. in the field of breast cancer have made attempts toexamine novel molecular healing marks. The identification of the clusteredregularly interspaced short palindromic repeats (CRISPR) CRISPRassociated protein ۹ (Cas۹) system an expanding supply of its medicinal havegiven a vital requirement for editing of the genomes of BC tumors. Intreatment, CRISPR/Cas۹ is used to improve gene therapy such as BRCA۱and BRCA۲ are critical genes involved in the pathogenesis of breast cancer.The CRISPR-based methods have been used as Nucleic Acid-BasedBiomarkers for Breast Cancer, diagnosed miRNA (mi- microRNA),circulating tumor DNA, cell-free DNA (cfDNA), and tumor-specificbiomarkers. The CRISPR-based outlined program was shown to decrease thegrowing tumor cells of evolution TNBC and their growth rate in rats up to ۷۷percent without any toxic impact on normal tissues and for applications inbreast cancer diagnostic acceptable devices.

Keywords:

Breast cancer , TNBC , BRCA۱ and BRCA۲ , CRISPR/Cas۹